Vol. 3 No. 11 (2023)
Reimbursement Reviews

Belzutifan (Welireg)

Published November 15, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Belzutifan (Welireg), 40 mg, tablets, oral.
  • Indication: For treatment of adult patients with von Hippel-Lindau disease who require therapy for an associated nonmetastatic renal cell carcinoma, central nervous system hemangioblastoma, or nonmetastatic pancreatic neuroendocrine tumour not requiring immediate surgery.